معرفی
Miles De Blasio is a Research Fellow in Drug Discovery Biology at Monash Institute of Pharmaceutical Sciences (MIPS), Monash University. He also holds adjunct and honorary roles as an Adjunct Research Fellow in Pharmacology at MIPS, Honorary Research Collaborator at the Baker Heart and Diabetes Institute, and Honorary Research Fellow at Monash Clayton’s Department of Pharmacology. His research focuses on novel therapies for diabetic cardiomyopathy, leveraging pharmacological agents and cardiac-selective gene therapies targeting pathways like the hexosamine biosynthesis pathway and adiponectin signaling.
De Blasio earned his PhD in 2004 from the University of Adelaide, studying diabetes and obesity origins in fetal growth-restricted sheep. He later worked at the University of Cambridge, exploring fetal leptin’s role in lung and heart development, before shifting to diabetic cardiomyopathy in 2015. Since 2020, he leads MIPS’ efforts to develop cardioprotective treatments.
His research interests emphasize translational cardiology and metabolic disease, with a focus on sex-specific differences, preclinical models, and therapeutic interventions. Projects include developing mouse models for diabetic cardiomyopathy and investigating next-generation glucose-lowering therapies’ cardiac benefits. He has secured over $7 million in grants as a Chief Investigator and supervised 10 PhD and 15 Honours students. His work contributes to UN Sustainable Development Goals related to health and well-being.
- Key Awards:
- Novartis Junior Investigator Award (Finalist, 2001)
- Ross Wishart Award (Finalist, 2001)
- Second Place, IGF Down Under Symposia Oral Presentation (2006)
- Second Place, GH-IGF International Conference Oral Presentation (2004)
- New Investigator Award, PSANZ (2002)
Advising & Grants: De Blasio has supervised numerous students and secured major funding through NHMRC grants and Diabetes Australia. His labs, including the Cardio-Metabolic Physiology Lab and co-headed Heart Failure Pharmacology Lab, drive interdisciplinary research in drug discovery and cardiac protection.
Labs & Collaborations: He leads the Cardio-Metabolic Physiology Laboratory at MIPS, collaborating with institutions like the Baker Heart and Diabetes Institute. Research spans cellular/molecular cardiology, mitochondrial function, and gene therapy applications in diabetes-related heart failure.
